Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29
      Google Scholar   
Citation:
546-547
Meeting Instance:
IMW 2019
Year:
2019
Type:
Abstract
Sub type:
Poster General
Funding:
AFT
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epreprint
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3304  
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Janssen Research & Development, LLC  
Grants:
 
Corr. Author:
 
Authors:
                                                           
Networks:
CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OH008, OR013   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: